Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Analysts have a consensus rating of Moderate Buy on Contineum Therapeutics (six firms: four Buy, one Hold, one Sell) with an average 1‑year price target of $19.50.
• CTNM opened at $13.25 and trades in a 12‑month range of $3.35–$16.33 with a market cap around $495 million; the company reported Q4 EPS of ($0.49), narrowly beating estimates, but analysts forecast about ($2.01) for the current fiscal year.
• Contineum is a clinical‑stage biopharma focused on oral small‑molecule therapies, led by PIPE‑791, a brain‑penetrant LPA1R inhibitor targeting idiopathic pulmonary fibrosis and progressive multiple sclerosis.

Contineum Therapeutics, Inc. (NASDAQ:CTNM - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $19.50.

A number of analysts recently issued reports on CTNM shares. Morgan Stanley reiterated an "equal weight" rating and issued a $14.00 price target (down from $23.00) on shares of Contineum Therapeutics in a report on Thursday, January 8th. Wall Street Zen lowered Contineum Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 7th. Robert W. Baird upped their target price on Contineum Therapeutics from $14.00 to $20.00 and gave the stock an "outperform" rating in a report on Friday, March 6th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Contineum Therapeutics in a research report on Wednesday, January 21st.

Contineum Therapeutics Price Performance

CTNM stock opened at $13.25 on Thursday. Contineum Therapeutics has a 12 month low of $3.35 and a 12 month high of $16.33. The firm's 50-day moving average is $13.96 and its 200 day moving average is $12.43. The company has a market capitalization of $494.76 million, a PE ratio of -6.08 and a beta of 1.38.

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.01. Sell-side analysts forecast that Contineum Therapeutics will post -2.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CTNM. Strs Ohio purchased a new position in Contineum Therapeutics during the 1st quarter valued at about $27,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Contineum Therapeutics in the 4th quarter worth approximately $43,000. Qube Research & Technologies Ltd purchased a new stake in shares of Contineum Therapeutics in the 2nd quarter worth approximately $43,000. Marex Group plc bought a new position in shares of Contineum Therapeutics during the second quarter valued at approximately $45,000. Finally, Bridgeway Capital Management LLC bought a new position in shares of Contineum Therapeutics during the second quarter valued at approximately $76,000.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.